Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 3, 2012, Pages 339-347

  Reddy, Karnati Konda ^a   Singh, Sanjeev Kumar ^a   Dessalew, Nigus ^b   Tripathi, Sunil Kumar ^a   Selvaraj, Chandrabose ^a  

^a ALAGAPPA UNIVERSITY   (India)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

3D QSAR; AIDS; HIV 1 IN; N methyl pyrimidones; Pharmacophore modelling

Indexed keywords

AROMATIC COMPOUND; HYDROGEN; INTEGRASE INHIBITOR; LIGAND; PYRIMIDINONE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; ATOM; CONTROLLED STUDY; DRUG POTENCY; ELECTRON; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; IC 50; NONHUMAN; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860352991     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.590803     Document Type: Article

References (29)

1. Weiss RA. How does HIV cause AIDS? Science 1993;260:1273-1279. (Pubitemid 23231970)
2. Cunningham AL, Donaghy H, Harman AN, Kim M, Turville SG. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol 2010;13:524-529.
3. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-1431. (Pubitemid 12240076)
4. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981;305:1431-1438. (Pubitemid 12240077)
5. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871. (Pubitemid 13080157)
6. Bushman FD, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA 1991;88:1339-1343. (Pubitemid 21916220)
7. Hagmann M. Study confirms effectiveness of antiretroviral drugs for HIV patients. Bull World Health Organ 2003;81:918-919.
8. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001;276:23213-23216.
9. d Angelo J, Mouscadet JF, Desmaële D, Zouhiri F, Leh H. HIV-1 integrase: the next target for AIDS therapy? Pathol Biol 2001;49:237-246. (Pubitemid 32299163)
10. Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 2010;65:2485-2488.
11. Goodarzi G, Im GJ, Brackmann K, Grandgenett D. Concerted integration of retrovirus-like DNA by human immunodeficiency virus type 1 integrase. J Virol 1995;69:6090-6097.
12. Chow SA, Vincent KA, Ellison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992;255:723-726.
13. Kukolj G, Skalka AM. Enhanced and coordinated processing of synapsed viral DNA ends by retroviral integrases in vitro. Genes Dev 1995;9:2556-2567.
14. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999;96:13040-13043.
15. Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 1992;66:6361-6369.
16. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994;266:1981-1986.
17. Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 1997;4:567-577. (Pubitemid 27282153)
18. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647-671. (Pubitemid 46023928)
19. Dixon SL, Smondyrev AM, Rao SN. PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 2006;67:370-372.
20. Phase 3.2, User manual. Schrödinger, New York, NY, 2010.
21. Phase, version 3.2. Schrödinger, New York, NY, 2010.
22. Gardelli C, Nizi E, Muraglia E, Crescenzi B, Ferrara M, Orvieto F et al. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. J Med Chem 2007;50:4953-4975. (Pubitemid 47525478)
23. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008;51:5843-5855.
24. Halgren TA. MMFF VI: MMFF94s option for energy minimization studies. J Comp Chem, 1999;20:720-729. (Pubitemid 129652635)
25. Evans DA, Doman TN, Thorner DA, Bodkin MJ. 3D QSAR methods: Phase and Catalyst compared. J Chem Inf Model 2007;47:1248-1257. (Pubitemid 46973738)
26. Narkhede S, Degani M. Pharmacophore refinement and 3D-QSAR studies of histamine H3 antagonists. QSAR Combinatorial Sci 2007;26:744-753. (Pubitemid 46984720)
27. Tawari NR, Bag S, Degani MS. Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators. J Mol Model 2008;14:911-921.
28. Li Y, Wang Y, Zhang F. Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors. J Mol Model 2010;16:1449-1460.
29. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inf 2010;29:476-488.